BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $126.00 price target on BioNTech (NASDAQ: BNTX).

The analyst comments "The ESMO Asia abstract (see inside) for the oral presentation for the Phase 1/2 trial evaluating BNT324 (B7-H3 ADC) in patients with solid tumors shows a competitive early profile, in our view. BNT324’s safety profile is in-line with ADCs on the market and early efficacy is encouraging, particularly in small cell lung cancer (SCLC), where 45.5% of patients responded, higher in patients with no prior topotecan (56.0%) or prior immuno-oncology (IO, 55.6%) treatments. BNT324’s profile appears potentially combinable, which fits into BNTX’s oncology development plans. We reiterate our Outperform rating."

For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.

Shares of BioNTech closed at $118.39 yesterday.

You May Also Be Interested In